New York, Feb 11, 2026, 06:16 EST — Premarket
- Abpro Holdings shares slid 16.8% ahead of the open, following a turbulent session the day before.
- Goldman Sachs has taken a 6.8% stake, according to a U.S. filing.
- Next week’s flow is on traders’ radar, along with the company’s earnings window coming up in late February.
Abpro Holdings, Inc. dropped 16.8% to $1.39 ahead of Wednesday’s open in the U.S., after a volatile session the previous day that got traders’ attention. On Tuesday, shares closed up 9.9% at $1.67, valuing the microcap biotech at roughly $4.5 million.
This is notable: ABP’s price action is more in line with momentum plays than your typical biotech. For stocks of this size, a lone headline or sparse order book can trigger the kind of swings you’d expect from an earnings report—particularly after hours, when liquidity tends to dry up.
The Goldman Sachs Group and its broker-dealer arm disclosed a 6.8% stake in Abpro, holding 196,537 shares as of Dec. 31, 2025, according to a Schedule 13G filed with the U.S. Securities and Exchange Commission. Schedule 13G filings, typically reserved for passive investors with more than a 5% stake, provide streamlined ownership details.
Abpro shares swung sharply on Tuesday, starting at $2.56, peaking at $2.89, then dropping to $1.65 before closing out the session at $1.67. Volume spiked to roughly 74.3 million shares, jumping from about 14.2 million the previous day, Nasdaq data via Yahoo Finance showed.
Goldman described the share purchase as part of its “ordinary course of business,” emphasizing there’s no intent to alter or steer control of the company. According to the filing, the bank reported no sole voting or dispositive power—everything falls under shared authority. SEC
Burlington, Massachusetts-based Abpro is pushing ahead with antibody therapies and teaming up with Celltrion on its main cancer project, ABP-102/CT-P72. “This IND clearance marks an important step for Abpro,” Chief Executive Miles Suk said in January, after the U.S. Food and Drug Administration signed off on the company’s Investigational New Drug application—the green light needed to start human trials.
The stake disclosure, though, is pegged to year-end—so it doesn’t confirm this is a new position. With the stock’s market value and float, sharp swings aren’t unusual. Premarket action often evaporates when the bell rings and volume kicks in.
All eyes now shift to late February, when the company is slated to report results—MarketWatch lists Feb. 25 as the date to watch. There’s a lot riding on what Abpro says about its cash position, any fresh financing moves, and progress toward kicking off that Phase 1 study, which is penciled in for the first half of 2026.
